Total submissions: 2
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV002966865 | SCV003283453 | uncertain significance | not provided | 2022-09-27 | criteria provided, single submitter | clinical testing | This sequence change replaces proline, which is neutral and non-polar, with serine, which is neutral and polar, at codon 565 of the TONSL protein (p.Pro565Ser). This variant is present in population databases (rs147880958, gnomAD 0.08%). This variant has not been reported in the literature in individuals affected with TONSL-related conditions. Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is expected to disrupt TONSL protein function. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. |
Ambry Genetics | RCV004681578 | SCV005177770 | uncertain significance | Inborn genetic diseases | 2024-06-11 | criteria provided, single submitter | clinical testing | The c.1693C>T (p.P565S) alteration is located in exon 14 (coding exon 14) of the TONSL gene. This alteration results from a C to T substitution at nucleotide position 1693, causing the proline (P) at amino acid position 565 to be replaced by a serine (S). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |